Primary care of the kidney transplant recipient

Primary care of the kidney transplant recipient

1. Fluvastatin, pravastatin, and atorvastatin seem to have a more favorable safety profile in kidney transplant recipients.

2. Because there is no evidence that a particular class of antihypertensive agents is more effective than other classes, the choice of medications should be individualized and based on various comorbidities.

3. Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines suggest goal blood pressure less than 130/80 mm Hg for all kidney transplant recipients.

4. NODAT should be carefully monitored for and develops in up to 54% of kidney transplant patients, particularly in the first 6 months.

5. Studies have demonstrated a rapid decrease in bone mineral density in the first 6 to 12 months after transplantation.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top